Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.39 +2.1%	$7.72	$4.11 ▼ $9.50	$1.75B	1.75	2.81 million shs	3.21 million shs
CGON CG Oncology	$22.37 +3.9%	$23.61	$14.80 ▼ $46.99	$1.70B	1.24	740,605 shs	1.64 million shs
IDRA Idera Pharmaceuticals		$0.50	$0.22 ▼ $8.67	$450.52M	1.25	464,030 shs	21,870 shs
KYMR Kymera Therapeutics	$33.26 -0.9%	$29.89	$19.45 ▼ $53.27	$2.16B	2.22	556,172 shs	500,969 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	+13.38%	+7.15%	+9.82%	+99.29%
CGON CG Oncology	0.00%	+8.38%	-16.96%	-27.35%	-37.95%
IDRA Idera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
KYMR Kymera Therapeutics	0.00%	+28.07%	+10.13%	-25.02%	-5.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.4671 of 5 stars	4.4	2.0	0.0	4.2	3.4	1.7	0.6
CGON CG Oncology	1.3225 of 5 stars	3.5	0.0	0.0	0.0	3.7	0.0	0.0
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	1.7495 of 5 stars	3.4	2.0	0.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.86	Moderate Buy	$15.57	85.60% Upside
CGON CG Oncology	3.00	Buy	$59.33	165.24% Upside
IDRA Idera Pharmaceuticals	0.00	N/A	N/A	N/A
KYMR Kymera Therapeutics	2.87	Moderate Buy	$56.36	69.44% Upside

Current Analyst Ratings Breakdown

Latest IDRA, KYMR, BCRX, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	CGON CG Oncology	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$23.00
4/11/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $11.00
4/10/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/31/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/25/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/13/2025	KYMR Kymera Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$52.00
3/7/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$55.00 ➝ $55.00
2/28/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$54.00 ➝ $60.00
2/25/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $11.00
2/25/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$15.00
2/25/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	3.89	N/A	N/A	($2.22) per share	-3.78
CGON CG Oncology	$1.14M	1,496.90	N/A	N/A	($1.94) per share	-11.53
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	0.29	$0.56 per share	N/A
KYMR Kymera Therapeutics	$47.07M	45.89	N/A	N/A	$7.12 per share	4.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$226.54M	-$0.43	N/A	N/A	N/A	-30.01%	N/A	-24.06%	5/5/2025 (Estimated)
CGON CG Oncology	-$48.61M	-$1.42	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	5/8/2025 (Estimated)
IDRA Idera Pharmaceuticals	$98.09M	-$0.32	N/A	N/A	N/A	N/A	-68.74%	-34.26%	N/A
KYMR Kymera Therapeutics	-$146.96M	-$2.97	N/A	N/A	N/A	-191.26%	-24.96%	-20.27%	5/1/2025 (Estimated)

Latest IDRA, KYMR, BCRX, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.93	N/A	N/A	N/A	$11.38 million	N/A
5/8/2025	Q1 2025	CGON CG Oncology	-$0.36	N/A	N/A	N/A	N/A	N/A
5/5/2025	Q1 2025	BCRX BioCryst Pharmaceuticals	-$0.07	N/A	N/A	N/A	$126.83 million	N/A
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million
2/27/2025	Q4 2024	KYMR Kymera Therapeutics	-$0.76	-$0.88	-$0.12	-$0.88	$14.81 million	$7.39 million
2/24/2025	Q4 2024	BCRX BioCryst Pharmaceuticals	-$0.07	-$0.13	-$0.06	-$0.13	$126.64 million	$131.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.78	2.73
CGON CG Oncology	N/A	35.32	35.32
IDRA Idera Pharmaceuticals	N/A	1.56	1.56
KYMR Kymera Therapeutics	N/A	8.55	8.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CGON CG Oncology	26.56%
IDRA Idera Pharmaceuticals	12.18%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
CGON CG Oncology	N/A
IDRA Idera Pharmaceuticals	5.05%
KYMR Kymera Therapeutics	15.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	208.96 million	197.19 million	Optionable
CGON CG Oncology	61	76.22 million	N/A	Optionable
IDRA Idera Pharmaceuticals	32	62.36 million	59.21 million	Optionable
KYMR Kymera Therapeutics	170	64.94 million	54.52 million	Optionable

IDRA, KYMR, BCRX, and CGON Headlines

Recent News About These Companies

Kymera Therapeutics (KYMR) Projected to Post Earnings on Thursday

April 26 at 4:02 AM | marketbeat.com

Why Kymera Therapeutics Stock Crushed it This Week

April 25 at 6:03 PM | fool.com

Kymera Therapeutics to unveil new oral development candidate

April 25 at 9:29 AM | markets.businessinsider.com

Why Kymera Therapeutics, Inc.’s (KYMR) Stock Is Up 5.21%

April 24 at 6:25 PM | aaii.com

Kymera Therapeutics Advances KT-621 Clinical Trials in Atopic Dermatitis and Asthma

April 23, 2025 | nasdaq.com

Kymera Therapeutics (NASDAQ:KYMR) Trading 6.2% Higher - What's Next?

April 23, 2025 | marketbeat.com

Avoro Capital Advisors LLC Boosts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

April 23, 2025 | marketbeat.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Rock Springs Capital Management LP

April 23, 2025 | marketbeat.com

Kymera Therapeutics announces first patient dosed in BROADEN Phase 1b trial

April 23, 2025 | markets.businessinsider.com

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

April 22, 2025 | globenewswire.com

Nan Fung Group Holdings Ltd Purchases 20,000 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

April 21, 2025 | marketbeat.com

Affinity Asset Advisors LLC Buys Shares of 40,000 Kymera Therapeutics, Inc. (NASDAQ:KYMR)

April 17, 2025 | marketbeat.com

Geode Capital Management LLC Has $44.48 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

April 16, 2025 | marketbeat.com

Alliancebernstein L.P. Decreases Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

April 16, 2025 | marketbeat.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Fmr LLC

April 15, 2025 | marketbeat.com

14,126 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by ExodusPoint Capital Management LP

April 14, 2025 | marketbeat.com

Norges Bank Buys New Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

April 13, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.9% - What's Next?

April 11, 2025 | marketbeat.com

Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?

April 10, 2025 | zacks.com

Kymera Therapeutics appoints Goodman as Chief Business Officer

April 9, 2025 | msn.com

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

April 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDRA, KYMR, BCRX, and CGON Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.39 +0.17 (+2.07%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$8.32 -0.07 (-0.82%)

As of 04/25/2025 07:57 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

CG Oncology NASDAQ:CGON

$22.37 +0.85 (+3.95%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$27.61 +5.24 (+23.41%)

As of 04/25/2025 07:59 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Idera Pharmaceuticals NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Kymera Therapeutics NASDAQ:KYMR

$33.26 -0.30 (-0.89%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$33.28 +0.02 (+0.08%)

As of 04/25/2025 04:05 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time